Furiex Pharmaceuticals (FURX) Narrows Q3 Loss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts FURX Hot Sheet
Join SI Premium – FREE
Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) reported Q3 loss of ($1.32), versus ($2.14) reported last year. Revenue for the quarter came in at $1.27 million, versus $288 thousand reported last year.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Southwest Gas (SWX) Tops Q3 EPS by 2c; Offers Guidance
- SelectQuote, Inc. (SLQT) Tops Q1 EPS by 13c ; Offers Guidance
- Flutter Entertainment plc (FLUT) Misses Q3 EPS by 525c; lowers guidance
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
